Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia

Trial Profile

Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
    • 12 Dec 2017 Results assessing efficacy and safety of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top